# TIRANUS (NCT05661188)

> Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

No report yet. It can be ordered.

- Drugs tested: tiragolumab plus atezolizumab
- Indication: localized anal canal squamous cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05661188
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
- Conditions: Squamous Cell Carcinoma of the Anal Canal
- Interventions: Atezolizumab plus Tiraglolumab
- Enrollment: 45
- Primary outcome: Clinical complete response (CCR)
- Primary outcome: Clinical complete response (CCR) rate

## Indexed commentary on TIRANUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=tiranus-nct05661188